Vir and alnylam expand collaboration to advance rnai therapeutics for treatment of coronavirus infection, including covid-19

Vir and alnylam expand collaboration to advance rnai therapeutics for the treatment of coronavirus infection, including covid-19.alnylam pharma - recent alnylam advances in lung delivery technology suggest possible utility of sirnas in targeting sars-cov-2.alnylam pharmaceuticals - vir to lead development of potential coronavirus rnai therapeutic candidates, with co retaining option for 50-50 participation.alnylam pharma - focus on development of sirnas that alnylam identified that target highly conserved regions of coronavirus rnas.alnylam pharm - may elect to earn development, commercialization milestones & royalties on net sales of products for coronavirus program.
ALNY Ratings Summary
ALNY Quant Ranking